P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy
- DOI
- 10.64898/2026.09.10.26362787
- Published
- 2026-09-14
- Container
- Not recorded
- Publisher
- openRxiv
- Open access
- unknown
Credibility signals
uncertain Score 60/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- cautionPublication version: Identified as a preprint; peer review and later versions may change the record.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.64898/2026.09.10.26362787,
title = {P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy},
author = {Mark A. Brimble and Shaoyuan Tan and Sarah Buddle and Li-An K. Brown and Judith Breuer and Jeremy Chase Crawford},
year = {2026},
doi = {10.64898/2026.09.10.26362787},
url = {https://doi.org/10.64898/2026.09.10.26362787}
}RIS
TY - JOUR TI - P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy AU - Mark A. Brimble AU - Shaoyuan Tan AU - Sarah Buddle AU - Li-An K. Brown AU - Judith Breuer AU - Jeremy Chase Crawford PY - 2026 DO - 10.64898/2026.09.10.26362787 UR - https://doi.org/10.64898/2026.09.10.26362787 ER -
APA
Brimble, M. A., Tan, S., Buddle, S., Brown, L. K., Breuer, J., & Crawford, J. C. (2026). P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy. https://doi.org/10.64898/2026.09.10.26362787
Source records
- crossref · retrieved 2026-09-25T11:50:58.956Z